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Abstract
Background: There is controversy regarding how comorbidity impacts on colorectal cancer screening, especially in
the context of organised programmes. The aim of this study is to assess the effect of comorbidities on participation
in the Barcelona population-based colorectal cancer screening programme (BCCSP).
Methods: Cross-sectional study carried out in ten primary care centres involved in the BCCSP. Individuals aged
50 to 69, at average risk of colorectal cancer, who were invited to participate in the first round of the faecal
immunochemical test-based BCCSP were included (2011–2012). The main variable was participation in the BCCSP.
Comorbidity was assessed by clinical risk group status. Other adjusting variables were age, sex, socioeconomic
deprivation, visits to primary care, smoking, alcohol consumption and body mass index. Logistic regression
models were used to test the association between participation in the programme and potential explanatory
variables. The results were given as incidence rate ratios (IRR) and their 95% confidence intervals (CI).
Results: Of the 36,208 individuals included, 17,404 (48%) participated in the BCCSP. Participation was statistically
significantly higher in women, individuals aged 60 to 64, patients with intermediate socioeconomic deprivation,
and patients with more medical visits. There was a higher rate of current smoking, high-risk alcohol intake,
obesity and individuals in the highest comorbidity categories in the non-participation group. In the adjusted
analysis, only individuals with multiple minor chronic diseases were more likely to participate in the BCCSP
(IRR 1.14; 95% CI [1.06 to 1.22]; p < 0.001). In contrast, having three or more dominant chronic diseases was
associated with lower participation in the screening programme (IRR 0.76; 95% CI [0.65 to 0.89]; p = 0.001).
Conclusions: Having three or more dominant chronic diseases, was associated with lower participation in a
faecal immunochemical test-based colorectal cancer screening programme, whereas individuals with multiple
minor chronic diseases were more likely to participate. Further research is needed to explore comorbidity as
a cause of non-participation in colorectal cancer screening programmes and which individuals could benefit
most from colorectal cancer screening.
Keywords: Colorectal neoplasm, Early detection of cancer, Mass screening, Primary health care, Chronic
disease, Comorbidity, Public health
* Correspondence: cguiriguet@gmail.com; cguiriguet.bnm.ics@gencat.cat
2Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari
d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Spain
5Family Medicine Department, Catalan Institute of Health, Barcelona, Spain
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Guiriguet et al. BMC Cancer  (2017) 17:524 
DOI 10.1186/s12885-017-3516-x
Background
In Western countries, colorectal cancer has the highest
incidence rate of all cancers and is the second leading
cause of cancer death in both sexes [1]. Evidence from
several studies has demonstrated that colorectal cancer
screening is effective and cost-effective in terms of redu-
cing disease-specific mortality in average-risk populations
through the detection of early-stage adenocarcinomas and
the detection and removal of adenomatous polyps [2].
Recommended colorectal cancer screening strategies fall
into two categories: stool tests that primarily detect can-
cer, which involve the detection of occult blood or exfoli-
ated DNA; and structural exams, which are effective in
detecting both cancer and premalignant lesions and
include flexible sigmoidoscopy, colonoscopy, and com-
puted tomography colonography [3]. Of these techniques,
the guaiac faecal occult blood test and, more recently, the
faecal immunochemical test (FIT) are the ones that are
used most frequently in European colorectal cancer
screening programmes [4]. In contrast, colonoscopy is the
dominant screening modality in North America [3]. Fol-
lowing European Union recommendations [5], colorectal
cancer screening programmes have been implemented
progressively in Spain in recent years and have involved
men and women aged 50 to 69 at average risk of develop-
ing colorectal cancer. Nonetheless, participation in these
programmes, with the exception of some regions, has not
reached the desired rate [6]. Several factors influence
participation in cancer screening. The most significant
factors are factors related to the healthcare system and
intrapersonal factors [7]. The former can be minimised
as an obstacle in publicly organised programmes [4].
The latter include social, cultural and psychological is-
sues (e.g. knowledge about a specific disease, the bene-
fits of screening, and the perceived risk, benefits,
barriers) which may, in turn, interact with one other in
a complex way [8].
Older age is associated with an increase in the preva-
lence of cancer and other chronic conditions or comor-
bidities, and questions remain about the interactions
between comorbidity and cancer screening participation
[9]. A recent systematic review and meta-analysis, focus-
ing on breast and cervical cancer, reported that results
from high quality studies suggested that women with a
comorbidity are less likely to participate in breast - and
possibly cervical - cancer screening, although a definitive
conclusion could not be drawn [10]. However, few
studies have focused on comorbid conditions and par-
ticipation on colorectal cancer screening [11–14]. On
the other hand, comorbidities influence the cost effective-
ness of screening, which depends on a patient’s current
diseases, individual background risk of developing colo-
rectal cancer, the previous screening history frequency
and life expectancy [15, 16]. The higher risk of death from
competing diseases at advanced ages and the risk of
screening induced harms (i.e. colonoscopy-related compli-
cations and over-diagnosis and over-treatment of colorec-
tal cancer), which increases with older age, tend to cancel
out the benefits of screening. The results of a study on the
appropriate age to stop colonoscopy screening (i.e., the
maximum age at which screening is cost-effective) given
sex, race, screening history, background risk of colorectal
cancer and comorbidity status showed that, while having
fewer comorbidities was associated with cost-effective
screening at older ages, sex and race had only a small ef-
fect on the appropriate age to stop screening [15]. Authors
concluded that colorectal cancer screening could be more
effective and cost effective if each patient’s individual fac-
tors were taken into account [15].
In this scenario, learning about how existing comor-
bidities affect key performance indicators for colorectal
cancer screening programmes must be a priority. In the
Barcelona Colorectal Cancer Screening Programme
(BCCSP), men and women aged 50 to 69 are invited to a
FIT every 2 years [17]. Individuals receive a mailed invi-
tation letter along with an explanatory leaflet. The FIT is
distributed through the community pharmacies involved
in the programme, and participants with a positive test
are invited to undergo a colonoscopy. Depending on the
result of colonoscopy, patients are referred to primary
care or specialists for follow-ups, or invited to re-enter
the programme. Both primary care professionals and
pharmacists receive a specific training session at the
beginning of each screening round, during which they
learn about the implementation of the programme.
The role of primary care professionals is to help the
programme to narrow down the target population,
identifying individuals with the exclusion criteria, and
to promote participation. In the context of the BCCSP,
this study is part of the Colo-alert [18], a cluster ran-
domised clinical trial in primary care. The aim of this
ad hoc analysis is to assess the association between co-
morbidities and colorectal cancer screening uptake in
the context of an organised FIT-based programme.
Methods
Study setting and population
Cross-sectional study carried out at 10 Barcelona pri-
mary care centres involved in the BCCSP from July 2011
to May 2012. The inclusion criterion for this ad hoc ana-
lysis was individuals eligible to participate in the first
round of the BCCSP (i.e. men and women aged 50 to 69
at average risk of colorectal cancer) included in the
Colo-alert trial (n = 41,042) [18]. The exclusion criterion
for this ad hoc analysis was the presence of BCCSP ex-
clusion criteria (n = 3100). Individuals with missing data
on comorbidities were excluded (n = 1734; 4.6%). In the
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end, a total of 36,208 individuals were included in the
study (Fig. 1).
The Colo-alert trial was a cluster randomised clinical
trial (RCT) in primary care, that evaluated the effective-
ness of an alert in the electronic medical record (inter-
vention group) to encourage colorectal cancer screening
participation compared to usual care (control group) in
which primary care professionals were involved in order
to improve colorectal cancer screening participation
[19]. The BCCSP was launched in December 2009 and
the first round lasted until May 2012. The target popula-
tion comprised 197,795 individuals invited based on the
primary care centre they had been assigned to. More
specifically, the specific cohort of individuals enrolled in
the cluster-RCT included those individuals assigned to
the last 10 primary care centres that were invited from
July 2011 to May 2012. These centres, run by the
Catalan Institute of Health, were waiting to start the first
round of the BCCSP at the time the intervention was
started. Of the 11 primary care centres invited to take
part in the RCT (n = 148 general practitioners -GP- and
57,020 patients), one refused to participate (n = 18 GP
and 5953 patients). Subsequently, 10,025 patients who
did not have a GP assigned to a participating centre at
the start of the study were excluded. Therefore, they
were not eligible to receive the RCT intervention.
Following the above exclusions, we considered the ap-
propriateness of including the entire population - 130
GP with 41,042 individuals.
Variables and data source
The main dependent variable was participation in the
BCCSP within 1 year of the date of invitation.
The main explanatory variable was comorbidity ac-
cording to clinical risk group (CRG) status [20]. The
Catalan Institute of Health incorporated the CRG tool as
a model for grouping morbidities. Its use involves a
computerised calculation based on a patient’s basic in-
formation as collected in their electronical medical rec-
ord (age, sex, International Classification of Diseases 10)
and the assignment and visualisation of the CRG stratifi-
cation results for each user in the computerised medical
record used by GP. The CRG status includes the fol-
lowing nine categories:
Fig. 1 Flowchart of the study. 1Corresponding to individuals involved in the cluster randomized controlled trial Colo-alert (see reference [19]).
2Colonoscopy performed in the last five years or faecal occult blood test in the last two years. BCCSP: Colorectal Cancer Screening Programme
of Barcelona
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Healthy (CRG 1)
Absence of any primary chronic diseases or significant
acute disease episodes or episode procedure categories.
History of significant acute disease (CRG 2)
Presence within the last 6 months of one or more sig-
nificant acute disease episode categories (i.e., chest pain)
or significant episode procedure categories with no pri-
mary chronic diseases present.
Single minor chronic disease (CRG 3)
Presence of a single minor primary chronic disease (i.e.,
migraine headache, hearing loss, hyperlipidaemia).
Minor chronic disease in multiple organ systems (CRG 4)
Presence of two or more minor primary chronic
diseases.
Single dominant or moderate chronic disease (CRG 5)
presence of a single dominant (i.e., congestive heart
failure, diabetes) or moderate (i.e., asthma, epilepsy) pri-
mary chronic disease.
Significant chronic disease in multiple organ systems
(CRG 6)
Presence of two or more primary chronic diseases, of
which at least one is a dominant or moderate primary
chronic disease.
Dominant chronic disease in three or more organ systems
(CRG 7)
Presence of three or more dominant primary chronic
diseases.
Dominant and metastatic malignancies (CRG 8)
A malignancy that dominates the medical care required
(i.e. brain malignancy) or a metastatic non-dominant
malignancy (i.e., prostate malignancy).
Catastrophic conditions (CRG 9)
Long-term dependency on a medical technology (i.e.,
dialysis, respirator) and life-defining chronic diseases or
conditions that dominate the medical care required (i.e.,
persistent vegetative state, cystic fibrosis, acquired im-
munodeficiency syndrome, history of heart transplant).
Other adjusting explanatory variables were age, sex,
body mass index (BMI), smoking status (never smoked,
ex-smoker, current smoker), alcohol consumption
(non-drinker, low-risk drinker, high-risk drinker), socio-
economic deprivation index, number of visits to pri-
mary care during the follow-up period (1 year) and the
study group to which individuals were allocated in the
Colo-alert study [19] (control or intervention). BMI
was grouped into three categories comprising low-normal
weight (<25 kg/m2), overweight (25–29.9 kg/m2) and
obesity (≥30 kg/m2). A high-risk alcohol drinker was
someone who drinks regularly (i.e. more than 4 standard
drinks per day for men, or more than 2 standard drinks
for women) or who binge drinks (defined as drinking at
least 5 standard drinks for men or 4 for women, in one sit-
ting). The socioeconomic deprivation index was based on
the results of the Medea Project [21], using five simple
ecological indicators from the 2001 census (unemploy-
ment, manual workers, casual workers, poor level of edu-
cation and poor level of education among young people)
[21]. For the city of Barcelona, five socioeconomic level
groups were constructed based on census tract quin-
tiles for the city, with the first quintile category (Q1)
representing the least deprived, to the fifth quintile
category (Q5) representing the most deprived.
The information on the target population for the colo-
rectal cancer screening programme was taken from the
Central Registry of Insured People in the Primary
Healthcare Information System. At the beginning of the
RCT the BCCSP technical office provided a list of
individuals who had been invited to participate in the
programme and their corresponding primary care
centre. All individuals’ characteristics were obtained
from the patients’ electronic medical record and pro-
vided by the Catalan Institute of Health’s Primary Care
Services Information System at the beginning of the
study; information regarding an individual’s participation
in the screening programme was provided by the
BCCSP. Data anonymity was guaranteed throughout the
whole study process.
Statistical analysis
All the individuals eligible for the study were included,
so no sampling was performed. Results are expressed as
a frequency and percentage for categorical variables, and
mean and standard deviation for continuous variables.
Statistically significant differences (p < 0.05) between
participants and non-participants in the program were
evaluated using chi-squared tests (categorical variables)
and Student’s t-test (continuous variables). Bivariate and
multivariate Poisson regression was used to test the as-
sociation between participation in the program and po-
tential explanatory variables, individually and mutually
adjusted, and the results were expressed in incidence
rate ratios (IRR) and their 95% confidence intervals (CI).
Exposure was set constant for all the participants. No
imputation of missing values was performed. Most of
the relevant adjusting variables had no missing values.
The CRG variable was analysed using the original nine
categories and also grouping them into four categories
(i.e., healthy or acute disease, minor chronic disease,
dominant chronic disease, malignancies or catastrophic
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diseases). All analyses were bilateral and performed with
Stata v14 software.
Results
Of the initial population, 3100 subjects were excluded as
they met the exclusion criteria for participation in the
BCCSP and 1734 were excluded as there was no comor-
bidity information available for them. In comparison
with the group of patients included in the study, in the
group of patients with no information on the variable
CRG status we observed a greater proportion of men
(54% vs. 46%), of individuals in the fifth deprivation
quintile (25% vs. 19%), of individuals who did not attend
their health centre in the last year (55% vs. 23%) and of
smokers (34% vs. 24%). The differences were statistically
significant for all the variables mentioned (p < 0.001). In
the end, a total of 36,208 individuals were included in
the study (Fig. 1); the average age was 59 years and 54%
were women. Healthy individuals constituted 22.1% of
the sample, and just over half of individuals had one
(26.8%) or two (29.4%) dominant chronic diseases. 46.2%
of the study population had used primary healthcare
services five times or more within a 1 year period, and
almost a quarter of individuals had not used them once
(22.8%). The rest of individuals’ baseline characteristics
are provided in Table 1.
Overall, 17,404 (48%) individuals participated in the
BCCSP. The bivariate analysis showed a statistically sig-
nificant higher uptake in females, subjects aged 60 to 64,
individuals in the third socioeconomic deprivation quin-
tile, and those who attended their primary care centre
three or more times, especially in case of five or more
visits (Table 1). There was a higher proportion of current
smoking, high-risk alcohol intake or obesity in the non-
participation group compared to the participation group
(Table 1). Participation in the BCCSP was higher in indi-
viduals with existing multiple minor chronic diseases
(58.7%) compared to those in the other CRG categories
(p < 0.001) (Table 1). On the other hand, there was a
lower proportion of participants classified as healthy
(39.4%) and in the acute disease category (40.6%) in the
participation group compared to those who did not par-
ticipate in the screening. This lower participation was
also found in individuals in the categories made up of
the individual’s with the most comorbidities, especially
in the case of three or more dominant chronic diseases
(40.3%), malignancies (46.1%) or catastrophic conditions
(43.9%) (p < 0.001) (Table 1).
In the multivariate logistic regression analysis, this par-
ticipation trend observed in bivariate analysis was main-
tained (Table 2). Nevertheless, after adjusting for sex,
age, socioeconomic deprivation index, number of visits
and study group, only individuals with multiple minor
chronic diseases were more likely to participate in the
BCCSP (IRR 1.14; 95% CI [1.06 to 1.22]; p < 0.001)
(Table 2). In contrast, having more than one dominant
chronic disease was associated with lower adherence to
the screening programme, although this only reached
statistical significance with three or more chronic diseases
(IRR 0.76; 95% CI [0.65 to 0.89]; p = 0.001) (Table 2).
Adjusting for the socioeconomic deprivation index re-
duced the analysis sample from 36,208 to 33,943. How-
ever, univariate results for CRG status using the reduced
sample were virtually the same (data not shown). Addi-
tional adjustment for smoking, alcohol and body mass
index reduced the sample to 16,294 individuals due to
missing values for these three variables. In any case, the
IRR were very similar to those obtained with the first set
of adjusting variables, but with wider 95% confidence
intervals (data not shown).
Discussion
Summary
This study assessed the impact of comorbidity on FIT-
based colorectal cancer screening programme uptake in
men and women aged 50 to 69. Individuals with mul-
tiple minor chronic diseases were more likely to partici-
pate in the screening programme compared to healthy
subjects. In contrast, subjects who had three or more
dominant chronic diseases were less likely to participate
in the programme.
Comparison with existing literature
The total crude participation rate in the BCCSP (48%)
observed in this study reached the standard of more
than 45% referred to in the European guidelines [4]. It
was higher than the average colorectal cancer screening
rates in Spain (43.8%) [6], but lower than the results for
the programme in the Basque Country (64.3%) [22] in
Spain and other European colorectal cancer screening
programmes (UK: 57.4%) [23]. Like other Spanish pro-
grammes, participation was higher among women than
men [6]. Healthy individuals made up 22.1% of the
sample. In Spain, two surveys, nationally representative,
carried out in an adult population and with data self-
reported by the participants showed that 40% [24] and
16% [25] of the population did not have any of the
chronic diseases on a preselected list of prevalent
chronic diseases. The rate for individuals in the groups
with the highest level of comorbidities (i.e., three or
more dominant chronic diseases, malignancies or cata-
strophic conditions) was 2.9%, a figure similar to the
2.3% of bowel screening non-participants who had a
medical reason for not participating in the Scottish
programme [31].
To date, few studies have investigated the presence of
comorbidities in people who have been invited to take
part in a colorectal cancer screening programme.
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Table 1 Participation in the colorectal cancer screening programme by individuals’ characteristics
Total Colorectal cancer screening programme p
Non-participation Participation
n % n % n %
Sex <0.001
Male 16,650 46.0% 9059 54.4% 7591 45.6%
Female 19,558 54.0% 9745 49.8% 9813 50.2%
Age, years (mean, SD) 58.8 5.5 58.5 5.6 59.1 5.5 <0.001
Age groups (years) <0.001
50–54 10,561 29.2% 5898 55.8% 4663 44.2%
55–59 9492 26.2% 4961 52.3% 4531 47.7%
60–64 8757 24.2% 4215 48.1% 4542 51.9%
65–69 7398 20.4% 3730 50.4% 3668 49.6%
Socioeconomic deprivation index (quintiles) <0.001
Q1 6665 18.4% 3732 56.0% 2933 44.0%
Q2 6949 19.2% 3551 51.1% 3398 48.9%
Q3 6969 19.2% 3293 47.3% 3676 52.7%
Q4 6963 19.2% 3482 50.0% 3481 50.0%
Q5 6397 17.7% 3667 57.3% 2730 42.7%
Unknown 2265 6.3%
Visits to primary care <0.001
None 8248 22.8% 5406 65.5% 2842 34.5%
1–2 5880 16.2% 3296 56.1% 2584 43.9%
3–4 5369 14.8% 2604 48.5% 2765 51.5%
> =5 16,711 46.2% 7498 44.9% 9213 55.1%
CRG status <0.001
Healthy 8020 22.1% 4858 60.6% 3162 39.4%
Acute disease 64 0.2% 38 59.4% 26 40.6%
Minor chronic disease 4090 11.3% 2080 50.9% 2010 49.1%
Multiple minor chronic diseases 2622 7.2% 1083 41.3% 1539 58.7%
Single dominant chronic disease 9695 26.8% 4922 50.8% 4773 49.2%
Two dominant chronic disease 10,629 29.4% 5205 49.0% 5424 51.0%
Three or more dominant chronic disease 452 1.2% 270 59.7% 182 40.3%
Malignancies 406 1.1% 219 53.9% 187 46.1%
Catastrophic condition 230 0.6% 129 56.1% 101 43.9%
Collapsed CRG <0.001
Healthy or acute disease 8084 22.3% 4896 60.6% 3188 39.4%
Minor chronic diseases 6712 18.6% 3163 47.1% 3549 52.9%
Dominant chronic diseases 20,776 57.4% 10,397 50.0% 10,379 50.0%
Malignancies or catastrophic condition 636 1.7% 348 54.7% 288 45.3%
Smoking status <0.001
Never smoker 12,464 34.4% 5735 46.0% 6729 54.0%
Former smoker 7354 20.3% 3260 44.3% 4094 55.7%
Current smoker 6121 16.9% 3536 57.8% 2585 42.2%
Unknown 10,269 28.4%
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Furthermore, few studies have explored the effect of co-
morbidity on colorectal cancer screening participation
and results have been controversial. Some of them high-
light a positive association between screening uptake
and better health status [26, 27] as it is correlated with
perceived benefits that increase the likelihood of cancer
screening [27]. Others show this association in the event
of coexisting health problems or chronic diseases, given
that these subjects contact health services more often
than healthy people, and therefore can receive recom-
mendations for screening [26, 27]. A recent systematic
review focusing on facilitators and barriers to colorectal
cancer screening adherence reported that individuals with
a chronic disease, such as hypertension, cardiovascular
Table 1 Participation in the colorectal cancer screening programme by individuals’ characteristics (Continued)
Alcohol consumption <0.001
Non-drinker 14,661 40.5% 7103 48.4% 7558 51.6%
Low-risk drinker 8402 23.2% 3866 46.0% 4536 54.0%
High-risk drinker 656 1.8% 365 55.6% 291 44.4%
Unknown 12,489 34.5%
Body mass index (kg/m2) <0.001
< 25 5187 14.3% 2466 47.5% 2721 52.5%
25–29.9 8217 22.7% 3737 45.5% 4480 54.5%
≧30 6330 17.5% 3068 48.5% 3262 51.5%
Unknown 16,474 45.5%
Study groupa <0.001
Control 17,072 47.1% 9041 53.0% 8031 47%
Intervention 19,136 52.9% 9763 51.0% 9373 49%
Total 36,208 100% 18,804 52% 17,404 48%
SD standard deviation, CRG Clinical Risk Group
aStudy group of the Colo-alert cluster randomised controlled trial
Table 2 Multivariate multinomial regression analysis for participation in the colorectal cancer screening programme by clinical
risk groups
Unadjusted (n = 36,208) Adjustedb (n = 33,943)
IRR IC95% p IRR IC95% p
CRG status
Healthya 1 - - - 1 - - -
Acute disease 1.03 0.70 1.52 0.879 0.73 0.49 1.11 0.142
Minor chronic disease 1.25 1.18 1.32 <0.001 1.05 0.99 1.12 0.119
Multiple minor chronic diseases 1.49 1.40 1.58 <0.001 1.14 1.06 1.22 <0.001
Single dominant chronic idisease 1.25 1.19 1.31 <0.001 0.98 0.93 1.04 0.509
Two dominant chronic disease 1.29 1.24 1.35 <0.001 0.95 0.90 1.01 0.087
Three or more dominant chronic disease 1.02 0.88 1.19 0.782 0.76 0.65 0.89 0.001
Malignancies 1.17 1.01 1.35 0.039 0.87 0.74 1.01 0.067
Catastrophic condition 1.11 0.91 1.36 0.286 0.90 0.74 1.10 0.310
Collapsed CRG
Healthy or acute diseasea 1 - - - 1 - - -
Minor chronic diseases 1.34 1.28 1.41 <0.001 1.09 1.03 1.15 0.002
Dominant chronic diseases 1.27 1.22 1.32 <0.001 0.97 0.92 1.02 0.186
Malignancies or catastrophic condition 1.15 1.02 1.30 0.025 0.88 0.78 1.00 0.055
Statistically significant differences are showed in bold (p < 0.05).
FIT Faecal immunochemical test, IRR Incidence Rate Ratio, CRG Clinical Risk Group
aReference category
bAdjusted by sex, age, socioeconomic deprivation index, number of visits, study group of the Colo-alert cluster randomised controlled trial
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disease, diabetes, arthritis, ulcers, asthma or emphysema,
were more likely to participate in colorectal cancer screen-
ing, both for faecal occult blood tests and endoscopies
[27]. This systematic review included seven studies specif-
ically assessing the effect of having a chronic monitorable
disease on colorectal cancer screening adherence, of
which five reported the chronic disease as a significant fa-
cilitator [27]. In fact, two nationwide surveys performed in
Spain based on self-reported data found significant higher
compliance with colorectal cancer screening as the num-
ber of chronic conditions increased [24] or in the event of
an existing comorbidity [25].
Contrary to these results, we found an inverse associ-
ation between having a dominant chronic disease and
completion of FIT, although we could not assess the
interaction with the specific type of disease. Our results
were in line with those reported by Liu et al., who found
a significant negative association between three or more
chronic conditions and colorectal screening (i.e., faecal
occult blood test or colonoscopy) after adjusting for the
number of visits to primary care [13]. Therefore, the
number of medical visits should be included when the
effect of comorbidity on screening participation is ana-
lysed. Some authors have hypothesized that specific dif-
ferential impact of different comorbidities could explain
these differences, regardless of whether there are comor-
bidities or not, the number of diseases, and other com-
posite measures [12, 13, 28]. In that sense, hypertension
has been associated with higher participation in colorec-
tal cancer screening [14], whereas other studies found
other chronic diseases that demand significant time with
GP in the clinic for management, such as diabetes or
heart disease reduced the likelihood of being up to date
with screening [13]. In this regard, in our study we ob-
served how participation is higher in individuals with
multiple minor chronic diseases, possibly as they are in
more frequent contact with health services compared to
the healthy population and as they had a lower level of
comorbidity compared to subjects who had multiple
dominant chronic diseases, who participated less in the
colorectal cancer screening programme.
Since recommending screening among patients with
limited life expectancy for whom screening tests have lit-
tle benefit and may even be harmful, older people have
been a focus of research [11, 15, 29, 30]. Controversial
results have been found in people aged 65 years or older
with regard to the association between comorbidity and
colorectal cancer screening uptake, with the results ran-
ging from non-significant [28] to a weak association [11].
Feedback from GP suggested that some participants
invited had a specific medical reason (the highest num-
ber of comorbidities) for not being screened [31]. A
more holistic view will help us to determine which indi-
viduals are at an increased risk of developing colorectal
cancer or its precursor lesions, how these factors influence
participating in population programmes, and which indi-
viduals may benefit most from colorectal cancer screening
[31]. The role of GP has been changing with the introduc-
tion of organised programmes in which they do not dir-
ectly order screening tests, but rather have an essential
role in increasing participation and informing the target
population [32]. The primary care setting offers a chance
to address colorectal cancer screening issues with patients
who attend for other reasons. Taking into account back-
ground comorbidities, previous screening history, colorec-
tal cancer risk, and individual preferences for screening
could lead to a desirable informed-decision, optimizing
the benefits and cost effectiveness of colorectal cancer
screening. We should pay special attention to individuals
with chronic dominant diseases, individualising the risk/
benefit balance of screening.
Strengths and limits
The strengths of this study include a large sample popu-
lation at average risk of developing colorectal cancer, in
terms of age, sex, comorbidities and socioeconomic sta-
tus. The population of the 10 centres included in the
RCT is representative of the population invited to the
first round of screening in Barcelona based on the socio-
demographic data published. Comorbidities are associ-
ated with a major use of health resources and may
increase the opportunity of receiving a cancer screening
recommendation from a doctor. In this study, the num-
ber of visits to primary care was also reported and ap-
propriately analysed as a determining confounding
factor. To our knowledge, this is the first study using
CRG categories to assess the impact of comorbidity on a
colorectal cancer screening programme. In this regard,
in addition to the presence and the number of comor-
bidities, additional information, such as the severity of
the chronic disease (i.e., minor or dominant) or its dur-
ation (i.e., acute, chronic) was given. The scientific litera-
ture is heterogeneous, since no gold standard approach
exists for measuring comorbidity in the context of can-
cer [33]. The suitability of alternative measures may de-
pend on the research question and also availability of
data [33]. As a result, it is difficult to compare results
between studies with appropriate accuracy, because the
results are heavily dependent on the list of comorbidities
used in each study. When reporting the effect of comor-
bidity on cancer screening participation, comorbidities
have been measured in the literature as present or not,
as a number [12, 13, 24] and/or type [13, 14] of chronic
diseases, as well as using specific composite indicators
(i.e., Charlson score [11]). As a limitation of the present
study, we had no information about the specific type of
chronic conditions or the International Classification of
Diseases code, which meant we were unable to examine
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their interaction with the CRG categories assessed in the
study. It should be pointed out that the patients excluded
due to a lack of information on the comorbidity variable
had a clinical profile less favourable for colorectal cancer
screening participation. Nevertheless, the percentage of
exclusions for this reason was small (4.6%). As expected,
there was a not negligible percentage of missing lifestyle
data (i.e., smoking, alcohol), especially for body mass
index. This may be because weight, and hence body mass
index, is widely unmeasured in primary care databases
[34]. It is important to mention that this study had an
urban population as the BCCSP was carried out in the city
of Barcelona and more studies would be required to ex-
trapolate these data to the entire population at average
risk of developing colorectal cancer in Catalonia. This
study took place in the context of a FIT population-based
colorectal cancer screening programme, so the results
cannot be generalised to other colorectal cancer screening
tests (i.e., colonoscopy), although faecal testing is the most
frequently used type of testing in Europe.
Conclusions
Having more comorbidities, especially three or more
dominant chronic diseases, was associated with statisti-
cally significant lower participation in a FIT-based colo-
rectal cancer screening programme. On the other hand,
individuals with multiple minor chronic diseases were
more likely to participate in the colorectal cancer screen-
ing programme. More positive engagement by GP is re-
quired to overcome barriers and reach desirable colorectal
cancer screening rates, especially among individuals who
may benefit most from screening. However, at the same
time, it is also important to identify patients with medical
reasons for non-participation in order to reduce risks. Fur-
ther research is needed to support our findings and to
look into the burden of specific diseases, in addition to the
presence or number of chronic diseases, on colorectal
cancer screening uptake. We must continue to explore,
using qualitative research, comorbidities as a reason for
non-participation in colorectal cancer screening, especially
in the context of organised programmes, and design spe-
cific interventions for the target population.
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